Volume 11, Issue 2 (6-2024)                   Avicenna J Neuro Psycho Physiology 2024, 11(2): 57-64 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ionov I, D. Krasilova M, O. Lyubimova M, Morozova N, Maltseva L, Komikarov P. Induction of catalepsy in rats by NK1 receptor antagonist and early-life maternal separation synergistically: the involvement of CRF1 receptors. Avicenna J Neuro Psycho Physiology 2024; 11 (2) :57-64
URL: http://ajnpp.umsha.ac.ir/article-1-488-en.html
1- Head, Department of Neurometabolic Analysis, Centre on Theoretical Problems in Physical and Chemical Pharmacology, Russian Academy of Sciences, Moscow, 109029, Russia , newrology@yandex.ru
2- Senior Researcher, Department of Neurology, Centre on Theoretical Problems in Physical and Chemical Pharmacology, Russian Academy of Sciences, Moscow, 109029, Russia
3- Researcher, Department of Neurology, Centre on Theoretical Problems in Physical and Chemical Pharmacology, Russian Academy of Sciences, Moscow, 109029, Russia
4- Centre on Theoretical Problems in Physical and Chemical Pharmacology, Russian Academy of Sciences, Moscow, 109029, Russia
5- Timpharm LTD, Moscow, 117513, Russia
Abstract:   (158 Views)
A lower level of brain substance P (SP) is detected in Parkinson’s disease; apparently, central SP-ergic deficiency takes place in Parkinsonian patients. The pathogenic relevance of this abnormality is unknown.  Another understudied area is the influence of early-life adversities on Parkinsonism.  Here, we hypothesized that i) simulation of central SP hypoactivity by intracerebral injections of NK1 receptor antagonist can initiate catalepsy, a model of Parkinsonian bradykinesia and rigidity, ii) early-life maternal separation (MS) can influence the SP-dependent catalepsy; and iii) the above catalepsy can be regulated by the blockade of CRF1 receptors. The study was performed on Wistar rats. MS of pups was carried out at postnatal days 2-14 for 3 h per day. In adulthood (16-17 weeks of age), one hundred ninety-two males with MS history (weight 280-310 g) were examined behaviorally; catalepsy was assessed by a bar test. In undisturbed animals, i.c.v. administration of NK1 receptor antagonist L-733,060 at 10.0 ng produced clear catalepsy, the drug at the dose of 1.0 ng was ineffective.  MS  per se failed to exert catalepsy, however, in the MS-exposed rats, L-733,060 at 1.0 ng produced strong cataleptic response.  Thus, the blocker of NK1 receptors and MS supra-additively initiated  the development of catalepsy. This catalepsy was significantly reversed by NBI 35 965, an antagonist of CRF1 receptors.   Our findings show, for the first time, that the blockade of central NK1 receptors can induce catalepsy; this cataleptic response is synergistically potentiated by MS and is mediated by CRF1 receptors. These data suggests that the combination of central NK1 receptor hypofunctioning   and   neonatal stress may dysregulate  the extrapyramidal system. Apparently, the central processes mediated by NK1 and CRF1 receptors might  be potential therapeutic targets for Parkinsonism.


 
Full-Text [PDF 1321 kb]   (35 Downloads) |   |   Full-Text (HTML)  (16 Views)  
Article Type: Research Article | Subject: Movement disorders
Received: 2024/06/23 | Accepted: 2024/08/19 | Published: 2024/09/16

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY 4.0 | Avicenna Journal of Neuro Psycho Physiology

Designed & Developed by : Yektaweb